Market Place
Sourcing Support
InnoCare`s Orelabrutinib Data Presented At ESMO Congress 2024
13 Sep 2024 //
BUSINESSWIRE
InnoCare Announces Approval of BCL2 Inhibitor ICP-248 with Orelabrutinib
12 Mar 2024 //
BUSINESSWIRE
InnoCare Announces First Patient Dosed in the Phase III Trial of Orelabrutinib
26 Oct 2023 //
BUSINESSWIRE
Study Result of Orelabrutinib in Patients with r/r MZL Published
12 Sep 2023 //
BUSINESSWIRE
Latest Data of InnoCare`s Orelabrutinib Presented at the 17th (ICML)
15 Jun 2023 //
BUSINESSWIRE
Clinical Study Result of Orelabrutinib in Patients with R/R MCL
01 May 2023 //
BUSINESSWIRE
Biogen CEO says company `lost its way,` cuts $125M MS partnership amid declining revenue
16 Feb 2023 //
ENDPTS
Phase II Study of Orelabrutinib in Patients with R/R CLL/SLL Published
06 Feb 2023 //
BUSINESSWIRE
China’s CDE grants approval for InnoCare’s NHL therapy trial
21 Dec 2022 //
CLINICALTRIALSARENA
InnoCare Announces Approval to Conduct a Ph II Clinical Trial of Orelabrutinib
20 Dec 2022 //
BUSINESSWIRE
InnoCare Announces Approval of HIBRUKA (Orelabrutinib)
22 Nov 2022 //
BUSINESSWIRE
InnoCare Releases 2022 Third Quarter Results
14 Nov 2022 //
BUSINESSWIRE
10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH
07 Nov 2022 //
BUSINESSWIRE
China NMPA grants priority review for InnoCare’s orelabrutinib for lymphoma
06 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
InnoCare Announces Acceptance of Supplemental NDA for Orelabrutinib
12 Aug 2022 //
BUSINESSWIRE
Latest Data of InnoCare’s Orelabrutinib for SLE at LBA Session of EULAR 2022
05 Jun 2022 //
BUSINESSWIRE
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib
01 Mar 2022 //
PRNEWSWIRE
InnoCare Begins Dosing in Phase II Clinical Trial Using Orelabrutinib for ITP
22 Feb 2022 //
PRNEWSWIRE
InnoCare to Present Orelabrutinib Data atthe Upcoming 63rd Annual Meeting of ASH
09 Nov 2021 //
PRNEWSWIRE
Biogen taps Chinese biotech InnoCare in $125M MS drug pact
14 Jul 2021 //
FIERCEBIOTECH
InnoCare Presents Latest Clinical Data of Orelabrutinib at Conference
18 Jun 2021 //
PRNEWSWIRE
WuXi STA Supports Approval from NMPA for Orelabrutinib from InnoCare
11 Jan 2021 //
PHARMTECH
InnoCare Announces the Approval of Orelabrutinib in China for Patients with
28 Dec 2020 //
BUSINESSWIRE
China NMPA approves InnoCare’s orelabrutinib to treat patients with y CLL/ SLL
28 Dec 2020 //
PHARMABIZ
InnoCare Announces the Approval of Orelabrutinib in China for Patients with
28 Dec 2020 //
BUSINESSWIRE
China NMPA approves InnoCare’s orelabrutinib to treat patients with y CLL/ SLL
28 Dec 2020 //
PHARMABIZ
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.